Author/Authors :
Constantine G. Boojamra، نويسنده , , Rémy C. Lemoine، نويسنده , , Johanne Blais، نويسنده , , Nicole G. Vernier، نويسنده , , Karin A. Stein، نويسنده , , Angela Magon، نويسنده , , Suzanne Chamberland، نويسنده , , Scott J. Hecker، نويسنده , , Ving J. Lee، نويسنده ,
Abstract :
Dihydropacidamycins having an antibacterial spectrum modified from that of the natural product pacidamycins and mureidomycins have been synthesized. Synthetic dihydropacidamycins with noteworthy antibacterial activity against wild-type and resistant Escherichia coli have been identified (MIC=4–8 μg/mL). Some dihydropacidamycins are shown to have activity against multi-resistant clinical strains of Mycobacterium tuberculosis. Compounds of this class are inhibitors of the cell wall biosynthetic enzyme, MraY.
